SCHEMBL2660661

SCHEMBL2660661

CCCN1Cc2nc3c(-c4cncc(C#N)c4)cccc3c(N)c2C1=O

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BACE1 P56817 5/20 0.36
▸ BACE2 Q9Y5Z0 1/20 0.36
▸ USP7 Q93009 2/20 0.36
▸ HRH4 Q9H3N8 1/20 0.36
▸ GABRA1 P14867 1/20 0.35
▸ GABRG2 P18507 1/20 0.35
▸ GABRB3 P28472 1/20 0.35
▸ GABRA5 P31644 1/20 0.35
▸ GABRA3 P34903 1/20 0.35
▸ GABRA2 P47869 1/20 0.35
▸ GABRB2 P47870 1/20 0.35
▸ LMNA P02545 1/20 0.33
▸ PARP1 P09874 1/20 0.33
▸ HTT P42858 1/20 0.33
▸ PARP2 Q9UGN5 1/20 0.33
▸ BRD4 O60885 1/20 0.32
▸ BRD2 P25440 1/20 0.32
▸ BRD3 Q15059 1/20 0.32
▸ CREBBP Q92793 1/20 0.32
▸ P4HTM Q9NXG6 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2660726 0.90 ENPP1 (0.38) BACE1BACE2USP7HRH4LMNA
SCHEMBL2655841 0.83 DHPS (0.40) BACE1LMNAPARP1HTTPARP2
SCHEMBL2660637 0.82 LMNA (0.38) HRH4GABRG2GABRB3GABRA2LMNA
SCHEMBL2660242 0.82 SSTR5 (0.34) BACE1BACE2HRH4GABRA1GABRG2
SCHEMBL2661216 0.82 DPP4 (0.36) HRH4LMNAPARP1HTTPARP2
SCHEMBL2661039 0.81 BACE1 (0.33) BACE1BACE2USP7HRH4P4HTM
SCHEMBL2656723 0.81 GABRG2 (0.44) GABRG2GABRB3GABRA2LMNAPARP1
SCHEMBL2661035 0.81 BACE1 (0.40) BACE1BACE2USP7HRH4P4HTM
SCHEMBL4924382 0.81 LCK (0.49) LMNAPARP1HTTPARP2BRD4
SCHEMBL2660707 0.80 CRHR1 (0.41) HRH4GABRG2GABRB3GABRA2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2176263-A2 FUSED QUINOLINE DERIVATIVES USEFUL AS GABA MODULATORS AstraZeneca AB (SE) 2010-04-21 — — EP claimed
US-20080318943-A1 Compounds and Uses Thereof - 848 ASTRAZENECA AB (SE) 2008-12-25 — — US claimed
WO-2008155572-A2 FUSED QUINOLINE DERIVATIVES USEFUL AS GABA MODULATORS ASTRAZENECA AB (SE) 2008-12-24 — — WO claimed
EP-2176263-A2 FUSED QUINOLINE DERIVATIVES USEFUL AS GABA MODULATORS AstraZeneca AB (SE) 2010-04-21 — — EP disclosed
US-20080318943-A1 Compounds and Uses Thereof - 848 ASTRAZENECA AB (SE) 2008-12-25 — — US disclosed
WO-2008155572-A2 FUSED QUINOLINE DERIVATIVES USEFUL AS GABA MODULATORS ASTRAZENECA AB (SE) 2008-12-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080318943-A1 Compounds and Uses Thereof - 848 COMT, BACE1, BDNF BACE1 2/4885BACE2 54/4885USP7 871/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback